Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report)’s stock price rose 2.1% during mid-day trading on Thursday . The company traded as high as C$1.97 and last traded at C$1.95. Approximately 48,665 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 75,373 shares. The stock had previously closed at C$1.91.
Cardiol Therapeutics Trading Up 2.1%
The stock has a market capitalization of C$161.81 million, a PE ratio of -3.83 and a beta of 0.70. The business’s 50-day moving average is C$1.56 and its two-hundred day moving average is C$1.72. The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49.
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
- Five stocks we like better than Cardiol Therapeutics
- What is the FTSE 100 index?
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- Differences Between Momentum Investing and Long Term Investing
- 3 Stocks Set to Double—And There’s Still Time to Buy
- How to Short Nasdaq: An Easy-to-Follow Guide
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
